Welcome to our dedicated page for Adial Pharmaceuticals news (Ticker: ADIL), a resource for investors and traders seeking the latest updates and insights on Adial Pharmaceuticals stock.
Adial Pharmaceuticals Inc (ADIL) is a clinical-stage biopharmaceutical company pioneering personalized treatments for alcohol use disorder through advanced pharmacogenomics. This page provides investors and healthcare professionals with essential updates on ADIL's clinical trials, regulatory milestones, and strategic initiatives.
Access timely announcements about the company's lead investigational drug AD04—a serotonin-3 receptor antagonist designed for genetically identified patient groups. Stay informed about clinical study results, FDA communications, intellectual property developments, and partnership opportunities that demonstrate ADIL's progress in addiction medicine.
Key updates include progress reports on the 505(b)(2) regulatory pathway, companion diagnostic advancements, and peer-reviewed research publications. All content is curated to help stakeholders track the company's evidence-based approach to treating addictive disorders through precision medicine.
Bookmark this page for direct access to primary source materials and analysis-free reporting on ADIL's scientific and corporate developments. Check regularly for new filings, trial data disclosures, and strategic announcements that shape the company's trajectory in biopharmaceutical innovation.
Adial Pharmaceuticals announced positive results for PNV-5030, a treatment for chronic pain, demonstrating significant pain reduction in animal models. In a study involving rats, PNV-5030 reduced pain by up to 76% compared to placebo and showed higher efficacy than acetaminophen. The drug exhibited over 1000-fold selectivity over the A1 receptor and improved solubility by more than 50 times compared to similar compounds. This breakthrough could lead to advancements toward human clinical trials, enhancing Adial's drug development pipeline.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) has reported promising results for its PNV-6005, a selective adenosine 2A receptor agonist, in treating ulcerative colitis in an animal model. The study showed that PNV-6005 significantly reduced weight loss (over 50% inhibition) and prevented colon damage, suggesting strong anti-inflammatory properties. Conducted by experts at UC San Diego, the research aligns with Adial's strategy to advance this candidate towards human clinical trials amid a growing ulcerative colitis market projected to reach $10.8 billion by 2030.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) announced key leadership changes, appointing Cary J. Claiborne as President and CEO, succeeding William Stilley, who will lead Adial's subsidiary, Purnovate. Kevin Schuyler has been appointed Chairman of the Board. Claiborne's extensive experience includes previous roles at Indivior PLC and Sucampo Pharmaceuticals. The leadership transition aligns with Adial's goal to advance its lead drug, AD04, which aims to treat Alcohol Use Disorder. The firm plans to engage with regulatory bodies regarding promising Phase 3 trial results and explore partnership opportunities.
Adial Pharmaceuticals reported positive topline results from its ONWARD Phase 3 trial for AD04, targeting Alcohol Use Disorder (AUD). The trial indicated a statistically significant reduction in heavy drinking days among certain patients. The company plans to submit results to both the FDA and EMA while exploring partnership opportunities. As of June 30, 2022, cash and cash equivalents stood at $9.2 million, up from $6.1 million at the end of 2021. AD04's market potential is estimated to be multi-billion dollars in the U.S. alone.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) announced successful results from its ONWARD trial, demonstrating a significant reduction in heavy drinking days among patients with Alcohol Use Disorder (AUD). AD04, the company's investigational drug, achieved a 79% reduction in heavy drinking days and an 84% decline in AUD severity compared to placebo. These results support the drug's safety and tolerability. Adial plans to submit these findings to regulatory agencies in Europe and the U.S. for product approval and is considering strategic partnerships for further development.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) is set to report topline results from its ONWARD™ Phase 3 clinical trial on July 20, 2022. The trial assesses the efficacy and safety of AD04 in treating Alcohol Use Disorder in genetically screened patients. Conducted across 25 sites in six countries, it includes heavy and very heavy drinkers. Previous Phase 2b results indicated significant reductions in drinking frequency and quantity without serious safety concerns. The ongoing research may expand to other addictive disorders, highlighting the drug's potential impact.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) announced the database lock for its ONWARD™ Phase 3 trial, which is crucial for evaluating the efficacy of AD04 in treating Alcohol Use Disorder (AUD). With data now set, professional statisticians will analyze the results, with top-line findings expected by mid-July 2022. The ONWARD trial involves patients genetically screened for specific polymorphisms and is pivotal for FDA approval of AD04. Adial emphasizes the importance of its research in addiction medicine, reflecting a strong commitment to advancing treatment options.
Adial Pharmaceuticals has locked the database for its ONWARD Phase 3 clinical trial and transferred the data to independent statistical consultants for analysis. Results are expected to be announced in July 2022. The trial aims to evaluate the efficacy and safety of AD04 in reducing heavy drinking days among patients with Alcohol Use Disorder. Notably, no drug-related serious adverse events were reported. ONWARD is crucial for potential regulatory approval of AD04 based on targeted genetic screening of patients, paving the way for treatment options in alcohol addiction.
Adial Pharmaceuticals announced the issuance of patent number 11,351,154 on June 7, 2022, covering a genetic diagnostic panel linked to its lead product, AD04, aimed at treating Alcohol Use Disorder (AUD) and Opioid Use Disorder (OUD). This patent enhances their intellectual property portfolio, now exceeding 90 patents worldwide, ensuring market protection until at least 2031. With an estimated 35 million individuals in the U.S. suffering from AUD, the company anticipates significant opportunities in both AD04 and its diagnostic test. Results from the pivotal ONWARD Phase 3 trial are expected soon.
Adial Pharmaceuticals (NASDAQ: ADIL; ADILW) announced a research collaboration between its subsidiary, Purnovate, and the Medical College of Wisconsin. The focus is on developing adenosine analogs as treatments for diabetes and non-alcoholic steatohepatitis (NASH). The collaboration aims to test Purnovate's compounds in preclinical models, which could potentially address significant unmet medical needs. The global NASH market is projected to exceed $54 billion by 2027, highlighting the potential market impact of these developments.
